AngioDynamics Inc (AngioDynamics) designs, manufactures and markets minimal invasive and image-guided therapeutics and diagnostic devices. Its product portfolio encompasses vascular products, radiofrequency ablation and NanoKnife systems, vascular access products, angiographic products and accessories, products for dialysis, angioplasty, drainage, thrombolysis and embolization, besides venous products and renal therapy products. The company’s products find application in interventional radiology, interventional cardiology, and minimally-invasive diagnosis and treatment of cancer and peripheral vascular disease. It sells its products through direct sales force in the US and through a network of distributors outside the US, which include Latin America Europe, Asia, and others. AngioDynamics is headquartered in Latham, New York, the US.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
The report analyzes all pipeline products in development for the company AngioDynamics Inc
The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
The report provides detailed description of products in development, technical specification and functions
The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
To formulate effective Research & Development strategies
Develop market-entry and market expansion strategies
Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company
AngioDynamics Inc Company Overview
AngioDynamics Inc Company Snapshot
AngioDynamics Inc Pipeline Products and Ongoing Clinical Trials Overview
AngioDynamics Inc – Pipeline Analysis Overview
Business Description
AngioDynamics Inc - Key Facts
AngioDynamics Inc - Major Products and Services
AngioDynamics Inc Pipeline Products by Development Stage
AngioDynamics Inc Ongoing Clinical Trials by Trial Status
AngioDynamics Inc Pipeline Products Overview
Acuswift
Acuswift Product Overview
Alphavac F13 10
Alphavac F13 10 Product Overview
Alphavac F14 20
Alphavac F14 20 Product Overview
Alphavac System - Infective Endocarditis
Alphavac System - Infective Endocarditis Product Overview
Alphavac System - Left Atrial Appendage Thrombus
Alphavac System - Left Atrial Appendage Thrombus Product Overview
AngioVac - Generation 4
AngioVac - Generation 4 Product Overview
AngioVac - Left Heart
AngioVac - Left Heart Product Overview
AngioVac Low Profile Catheter
AngioVac Low Profile Catheter Product Overview
AURYON Atherectomy System - CAD
AURYON Atherectomy System - CAD Product Overview
AURYON Atherectomy System - Gastrointestinal Procedures
AURYON Atherectomy System - Gastrointestinal Procedures Product Overview
AURYON Atherectomy System - Iliofemoral DVT
AURYON Atherectomy System - Iliofemoral DVT Product Overview
AURYON Atherectomy System - Lead Extraction
AURYON Atherectomy System - Lead Extraction Product Overview
AURYON Atherectomy System - Venous Disease
AURYON Atherectomy System - Venous Disease Product Overview
AURYON System - Small Vessel Thrombectomy
AURYON System - Small Vessel Thrombectomy Product Overview
Automated Fluid Management System
Automated Fluid Management System Product Overview
BioFlo PICC Line Extension
BioFlo PICC Line Extension Product Overview
BioFlo Portline Line Extension
BioFlo Portline Line Extension Product Overview
Coronary Angio Catheter
Coronary Angio Catheter Product Overview
FireFly Tip Location
FireFly Tip Location Product Overview
Inflation Device
Inflation Device Product Overview
Mechanical Thrombectomy Device
Mechanical Thrombectomy Device Product Overview
Multi-Purpose Mechanical Aspiration - F1885 PE
Multi-Purpose Mechanical Aspiration - F1885 PE Product Overview
Multi-Purpose Mechanical Aspiration Gen 2
Multi-Purpose Mechanical Aspiration Gen 2 Product Overview
NanoKnife 3.0 System - Liver Cancer
NanoKnife 3.0 System - Liver Cancer Product Overview
NanoKnife 3.0 System - Pancreatic Cancer
NanoKnife 3.0 System - Pancreatic Cancer Product Overview
NanoKnife 3.0 System - Prostate Cancer
NanoKnife 3.0 System - Prostate Cancer Product Overview
Nanoknife System - Bladder Cancer
Nanoknife System - Bladder Cancer Product Overview
NanoKnife System - Cervical Cancer
NanoKnife System - Cervical Cancer Product Overview
NanoKnife System - Head And Neck Cancer
NanoKnife System - Head And Neck Cancer Product Overview
NanoKnife System - Hepatocellular Carcinoma
NanoKnife System - Hepatocellular Carcinoma Product Overview
NanoKnife System - Lung Cancer
NanoKnife System - Lung Cancer Product Overview
NanoKnife System - Lung Cancer Clinical Trial
Nanoknife System - Metastatic Lymph Nodes
Nanoknife System - Metastatic Lymph Nodes Product Overview
NanoKnife System - Prostate Cancer
NanoKnife System - Prostate Cancer Product Overview
NanoKnife System - Prostate Cancer Clinical Trial
NanoKnife System - Rectal Cancer
NanoKnife System - Rectal Cancer Product Overview
Nanoknife System - Renal Pelvis Urothelial Neoplasms
Nanoknife System - Renal Pelvis Urothelial Neoplasms Product Overview
NanoKnife System - Stage III Pancreatic Cancer
NanoKnife System - Stage III Pancreatic Cancer Product Overview
NanoKnife System - Stage III Pancreatic Cancer Clinical Trial
Nanoknife System - Stomach Neoplasm
Nanoknife System - Stomach Neoplasm Product Overview
Next Gen Tumescent Delivery Device
Next Gen Tumescent Delivery Device Product Overview
Next Generation BioFlo PICC
Next Generation BioFlo PICC Product Overview
Next Generation BioFlo Port
Next Generation BioFlo Port Product Overview
Next Generation Dialysis Device
Next Generation Dialysis Device Product Overview
Next Generation Laser
Next Generation Laser Product Overview
Next Generation Radio Frequency Ablation System
Next Generation Radio Frequency Ablation System Product Overview
Non-Thermal Vein Ablation Device
Non-Thermal Vein Ablation Device Product Overview
Peripheral Vascular Drainage Line Extension
Peripheral Vascular Drainage Line Extension Product Overview
Ultrasound-Assisted Thrombectomy System Product Overview
AngioDynamics Inc - Key Competitors
AngioDynamics Inc - Key Employees
AngioDynamics Inc - Key Employee Biographies
AngioDynamics Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
AngioDynamics Inc, Recent Developments
May 21, 2024: AngioDynamics Announces CE Mark Approval in Europe for AlphaVac F1885 System
May 06, 2024: AngioDynamics’ APEX-AV Trial Results Assessing AlphaVac F1885 System in Treatment of Pulmonary Embolism Presented at SCAI 2024 Scientific Sessions
May 03, 2024: Catheter-Directed Mechanical Thrombectomy System Demonstrates Safety and Effectiveness in Patients with Pulmonary Embolism
Apr 16, 2024: AngioDynamics Receives Additional FDA 510(k) Clearance for AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 System
Apr 04, 2024: Angiodynamics Receives 510(K) Clearance for Alphavac F1885 System in Treatment of PE
Jan 23, 2024: AngioDynamics Announces FDA 510(k) Clearance of Auryon XL Radial Access Catheter to Treat Peripheral Arterial Disease
Jan 05, 2024: AngioDynamics Reports Fiscal Year 2024 Second Quarter Financial Results; Revises Fiscal Year 2024 Guidance
Dec 07, 2023: AngioDynamics Completes Patient Enrollment in APEX-AV Study Assessing AlphaVac F1885 System in Treatment of Pulmonary Embolism
Aug 16, 2023: AngioDynamics’ AngioVac receives breakthrough device designation from FDA
Aug 03, 2023: Angiodynamics Completes Enrollment for Preserve Clinical Study
Table 54: Multi-Purpose Mechanical Aspiration Gen 2 - Product Status
Table 55: Multi-Purpose Mechanical Aspiration Gen 2 - Product Description
Table 56: NanoKnife 3.0 System - Liver Cancer - Product Status
Table 57: NanoKnife 3.0 System - Liver Cancer - Product Description
Table 58: NanoKnife 3.0 System - Pancreatic Cancer - Product Status
Table 59: NanoKnife 3.0 System - Pancreatic Cancer - Product Description
Table 60: NanoKnife 3.0 System - Prostate Cancer - Product Status
Table 61: NanoKnife 3.0 System - Prostate Cancer - Product Description
Table 62: Nanoknife System - Bladder Cancer - Product Status
Table 63: Nanoknife System - Bladder Cancer - Product Description
Table 64: NanoKnife System - Cervical Cancer - Product Status
Table 65: NanoKnife System - Cervical Cancer - Product Description
Table 66: NanoKnife System - Head And Neck Cancer - Product Status
Table 67: NanoKnife System - Head And Neck Cancer - Product Description
Table 68: NanoKnife System - Hepatocellular Carcinoma - Product Status
Table 69: NanoKnife System - Hepatocellular Carcinoma - Product Description
Table 70: NanoKnife System - Lung Cancer - Product Status
Table 71: NanoKnife System - Lung Cancer - Product Description
Table 72: NanoKnife System - Lung Cancer - A Novel Method for Treating Lung Metastases with the Combination of Electrical Fields and Radiation Therapy: A Single-arm Pilot Study
Table 73: Nanoknife System - Metastatic Lymph Nodes - Product Status
Table 75: NanoKnife System - Prostate Cancer - Product Status
Table 76: NanoKnife System - Prostate Cancer - Product Description
Table 77: NanoKnife System - Prostate Cancer - A Pilot Study Evaluating Safety and Efficacy of Transperineal Focal Irreversible Electroporation (IRE) of Anterior Prostate Cancer in Patients with an Intermediate Risk
Table 78: NanoKnife System - Prostate Cancer - Pivotal Study of the NanoKnife System for the Ablation of Prostate Tissue in an Intermediate-risk Patient Population
Table 79: NanoKnife System - Prostate Cancer - Registry of Irreversible Electroporation for the Ablation of Prostate Cancer with Use of Nanoknife Device; A Multi-center, International Registry to Evaluate the Treatment of Prostate Cancer in Terms of Recurrence, Functional Outcomes and Safety
Table 80: NanoKnife System - Rectal Cancer - Product Status
Table 81: NanoKnife System - Rectal Cancer - Product Description
Table 82: Nanoknife System - Renal Pelvis Urothelial Neoplasms - Product Status
Table 84: NanoKnife System - Stage III Pancreatic Cancer - Product Status
Table 85: NanoKnife System - Stage III Pancreatic Cancer - Product Description
Table 86: NanoKnife System - Stage III Pancreatic Cancer - A Phase 1 Study of Irreversible Electroporation and Pembrolizumab Immunotherapy in Locally Advanced Pancreatic Cancer
Table 87: NanoKnife System - Stage III Pancreatic Cancer - A Randomized, Multicenter, Controlled, Unblinded Study to Assess the Safety and Efficacy of the NanoKnife System for the Ablation of Unresectable Stage 3 Pancreatic Adenocarcinoma
Table 88: NanoKnife System - Stage III Pancreatic Cancer - Evaluation of the Short and Intermediate Term Outcomes of Ablation of Locally Advanced Unresectable Pancreatic Cancer Using the NanoKnife Irreversible Electroporation (IRE) System - A Prospective Study
Table 89: NanoKnife System - Stage III Pancreatic Cancer - Multicenter Clinical Trial of Widening the Applied Range of Steep Pulse (IRE)Therapy Instrument in Pancreatic Cancer
Table 90: NanoKnife System - Stage III Pancreatic Cancer - Registry to Evaluate Effectiveness and Safety of the NanoKnife System for the Ablation of Stage 3 Pancreatic Adenocarcinoma
Table 91: NanoKnife System - Stage III Pancreatic Cancer - Systemic Therapy with a Loco-regional Treatment in Patients with Locally Advanced Pancreatic Cancer: The SMART Study
Table 92: Nanoknife System - Stomach Neoplasm - Product Status
Table 93: Nanoknife System - Stomach Neoplasm - Product Description
Table 94: Next Gen Tumescent Delivery Device - Product Status
Table 95: Next Gen Tumescent Delivery Device - Product Description
Table 96: Next Generation BioFlo PICC - Product Status
Table 97: Next Generation BioFlo PICC - Product Description
Table 98: Next Generation BioFlo Port - Product Status
Table 99: Next Generation BioFlo Port - Product Description
Table 100: Next Generation Dialysis Device - Product Status
Table 101: Next Generation Dialysis Device - Product Description
Table 102: Next Generation Laser - Product Status
Table 103: Next Generation Laser - Product Description
Table 104: Next Generation Radio Frequency Ablation System - Product Status
Table 105: Next Generation Radio Frequency Ablation System - Product Description
Table 106: Non-Thermal Vein Ablation Device - Product Status